RE:Further clarity needed & size of mkt. I thought the efficacy data was vague, not in typical 'RECIST language' hard to gauge other than there is a little something there.
No mention of going back to FDA for chat so where's the path forward?
Also no suggestion of committing more cash.
So what then? Parked until partner???
Wino115 wrote: Some of those articles or reports make it seem like they will enhance the dose for whomever is still in the protocol. Bit confusing to me and they need to clarify next steps. I also had thought they always had the ability to add another 4-5 people after the high-dose was done if they wanted. Wasn't it always stated for part 3 as 6 at low-dose, 6 at high dose, potential to go 10 at high dose or more?
Lastly - 13,000 women die a year of ovarian and I would assume that's essentially their market as a heavily pre-treated therapy. It's still the fifth biggest cancer for women and growing in younger generations due to obesity (evidently).